BCAX
Bicara Therapeutics Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.36B
P/E Ratio
—
EPS
$-2.52
Beta
—
52W High
$21.63
52W Low
$7.80
50-Day MA
$17.49
200-Day MA
$14.98
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-155.50M |
| Operating Margin | 0.00% |
| Return on Equity | -30.90% |
| Return on Assets | -20.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.37 |
| Price-to-Book | 3.50 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $65.47M |
| Float | $42.32M |
| % Insiders | 10.25% |
| % Institutions | 88.39% |
Analyst Ratings
Consensus ($30.50 target)
2
Strong Buy8
Buy3
HoldData last updated: 4/7/2026